Revenue
$4.30B
Fiscal year ended 2025-12-31Operating income
$1.36B
Fiscal year ended 2025-12-31Free cash flow
$1.06B
Fiscal year ended 2025-12-31IDEXX LABORATORIES INC /DE (IDXX) reported revenue of $4.30B and net income of $1.06B for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from IDEXX LABORATORIES INC /DE’s SEC filings, each linked to the filing it came from. It is classified by the SEC under In Vitro & In Vivo Diagnostic Substances.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.30B | $3.90B | $3.66B | $3.37B | $3.22B | $2.71B | $2.41B | $2.21B | $1.97B | $1.78B |
| Cost of revenue | $1.64B | $1.52B | $1.47B | $1.36B | $1.33B | $1.14B | $1.04B | $971.70M | $871.68M | $799.99M |
| Gross profit | $2.66B | $2.38B | $2.19B | $2.00B | $1.89B | $1.57B | $1.37B | $1.24B | $1.10B | $975.44M |
| Operating income | $1.36B | $1.13B | $1.10B | $898.76M | $932.03M | $694.52M | $552.85M | $491.34M | $413.03M | $350.24M |
| Net income | $1.06B | $887.87M | $845.04M | $679.09M | $744.84M | $581.78M | $427.72M | $377.03M | $263.14M | $222.04M |
| Research & development | $251.21M | $219.79M | $190.95M | $254.82M | $161.01M | $141.25M | $133.19M | $117.86M | $109.18M | $101.12M |
| Weighted-average diluted shares | shares 81.02M | shares 83.25M | shares 83.98M | shares 84.60M | shares 86.57M | shares 86.72M | shares 87.54M | shares 88.47M | shares 89.57M | shares 90.88M |
| Pretax income | $1.32B | $1.11B | $1.06B | $859.97M | $902.65M | $661.98M | $522.22M | $457.74M | $381.06M | $321.85M |
| Income tax expense | $264.72M | $221.96M | $216.13M | $180.88M | $157.81M | $79.85M | $94.43M | $80.70M | $117.79M | $99.79M |
| Diluted EPS | $13.08 | $10.67 | $10.06 | $8.03 | $8.60 | $6.71 | $4.89 | $4.26 | $2.94 | $2.44 |
| Selling, general & administrative | $1.05B | $1.03B | $901.89M | $850.75M | $796.40M | $735.27M | $679.51M | $632.34M | $575.17M | $524.08M |
| General & administrative | $404.79M | $442.29M | $335.82M | $326.25M | $309.66M | $300.83M | $261.32M | $244.94M | $220.88M | $207.02M |
| Selling & marketing | $643.55M | $588.51M | $566.07M | $524.50M | $486.74M | $434.44M | $418.19M | $387.41M | $354.29M | $317.06M |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $180.07M | $288.27M | $453.93M | $112.55M | $144.45M | $383.93M | $90.33M | $123.79M | $187.68M | $154.90M |
| Total assets | $3.35B | $3.29B | $3.26B | $2.75B | $2.44B | $2.29B | $1.83B | $1.54B | $1.71B | $1.53B |
| Current assets | $1.41B | $1.40B | $1.50B | $1.10B | $955.66M | $1.06B | $679.64M | $654.17M | $971.98M | $845.58M |
| Total liabilities | $1.75B | $1.70B | $1.78B | $2.14B | $1.75B | $1.66B | $1.65B | $1.55B | $1.77B | $1.64B |
| Current liabilities | $1.15B | $1.07B | $951.55M | $1.24B | $763.58M | $582.76M | $725.34M | $770.44M | $1.00B | $934.57M |
| Total equity incl. NCI | $1.61B | $1.60B | $1.48B | $608.74M | $689.99M | $632.80M | $177.82M | -$9.23M | -$53.84M | -$108.21M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $377.76M | $381.88M | $380.28M | $367.82M | $269.03M | $209.87M | $195.02M | $173.30M | $164.32M | $158.03M |
| Accounts receivable | $552.38M | $473.58M | $457.44M | $400.62M | $368.35M | $331.43M | $269.31M | $248.86M | $234.60M | $204.49M |
| Goodwill | $414.00M | $405.10M | $366.00M | $361.80M | $359.34M | $243.35M | $239.72M | $214.49M | $199.87M | $178.23M |
| Long-term debt | $374.84M | $449.79M | $622.88M | $694.39M | $775.20M | $858.49M | $698.91M | $601.80M | $606.60M | $593.70M |
| Accounts payable | $110.41M | $114.21M | $110.64M | $110.22M | $116.14M | $74.56M | $72.17M | $69.53M | $66.97M | $60.06M |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.18B | $929.00M | $906.51M | $542.98M | $755.55M | $648.06M | $459.16M | $400.08M | $373.28M | Unavailable |
| Capital expenditures | $124.68M | $120.92M | $133.63M | $148.84M | $119.55M | $106.96M | $154.97M | $115.75M | $74.38M | $64.79M |
| Investing cash flow | -$136.24M | -$207.06M | -$125.25M | -$195.35M | -$292.97M | -$109.38M | -$205.53M | $138.60M | -$138.69M | Unavailable |
| Financing cash flow | -$1.16B | -$878.07M | -$442.00M | -$370.94M | -$697.41M | -$248.42M | -$286.41M | -$597.80M | -$208.02M | Unavailable |
| Net change in cash | -$108.20M | -$165.67M | $341.39M | -$31.91M | -$239.47M | $293.60M | -$33.47M | -$63.88M | $32.77M | $25.91M |
| Stock-based compensation | $60.01M | $60.30M | $59.74M | $49.77M | $37.76M | $30.95M | $39.28M | $25.16M | $23.52M | $19.89M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | $1.22B | $837.03M | $71.92M | $819.71M | $746.78M | $182.82M | $301.66M | $369.32M | $282.56M | $304.09M |
| Depreciation & amortization | $145.18M | $129.94M | $114.91M | $111.90M | $104.60M | $96.00M | $88.01M | $83.18M | $83.14M | $78.22M |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $1.06B | $808.08M | $772.88M | $394.15M | $636.00M | $541.10M | $304.19M | $284.33M | $298.89M | Unavailable |
| Gross margin | 61.8% | 61.0% | 59.8% | 59.5% | 58.8% | 58.0% | 56.7% | 56.1% | 55.7% | 54.9% |
| Operating margin | 31.6% | 29.0% | 30.0% | 26.7% | 29.0% | 25.7% | 23.0% | 22.2% | 21.0% | 19.7% |
| FCF margin | 24.6% | 20.7% | 21.1% | 11.7% | 19.8% | 20.0% | 12.6% | 12.8% | 15.2% | Unavailable |
| SBC / revenue | 1.4% | 1.5% | 1.6% | 1.5% | 1.2% | 1.1% | 1.6% | 1.1% | 1.2% | 1.1% |
| Current ratio | 1.23x | 1.31x | 1.57x | 0.89x | 1.25x | 1.82x | 0.94x | 0.85x | 0.97x | 0.90x |
| Revenue YoY growth | 10.4% | 6.5% | 8.7% | 4.7% | 18.8% | 12.5% | 8.8% | 12.4% | 10.9% | Unavailable |
| Net margin | 24.6% | 22.8% | 23.1% | 20.2% | 23.2% | 21.5% | 17.8% | 17.0% | 13.4% | 12.5% |
| R&D / revenue | 5.8% | 5.6% | 5.2% | 7.6% | 5.0% | 5.2% | 5.5% | 5.3% | 5.5% | 5.7% |
| CapEx / revenue | 2.9% | 3.1% | 3.7% | 4.4% | 3.7% | 4.0% | 6.4% | 5.2% | 3.8% | 3.6% |
| Long-term debt / equity | 0.23x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 20.0% | 20.0% | 20.4% | 21.0% | 17.5% | 12.1% | 18.1% | 17.6% | 30.9% | 31.0% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IDXX in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-20View SEC filing
10-Q · Filed 2025-11-03View SEC filing
10-Q · Filed 2025-08-04View SEC filing
10-Q · Filed 2025-05-01View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.